Analyst Maury Raycroft of Jefferies maintained a Buy rating on Kezar Life Sciences (KZR – Research Report), with a price target of $18.00.
Maury Raycroft has given his Buy rating due to a combination of factors related to Kezar Life Sciences’ promising clinical data and strategic plans. The company has demonstrated positive proof-of-concept results in their Phase II study for autoimmune hepatitis (AIH), showing significant biochemical response rates and successful steroid tapering, which are critical for treating refractory patients. Despite the small sample size, these results are clinically meaningful and position Kezar Life Sciences favorably in a market with no immediate competitors.
Furthermore, the company is actively working with the FDA to remove a partial clinical hold, which, if successful, will allow them to proceed with pivotal trial designs. The financial outlook is also strong, with sufficient cash reserves projected to last until late 2026. While there are some concerns about potential safety risks and variability in liver histology, the overall data supports the potential for significant therapeutic benefits, justifying the Buy rating.
According to TipRanks, Raycroft is a 4-star analyst with an average return of 4.9% and a 38.70% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sangamo Biosciences, and BioCryst.